Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results - CORVUS PHARMACEUTICALS INC

Financial Performance:

• R&D expenses rose to $17.8 million in Q3 2026 from $8.5 million in Q3 2025, driven by higher clinical trial costs for socalitinib and increased personnel costs.
• Net loss widened to $20.3 million in Q3 2026 compared to $10.2 million in Q3 2025; non-cash equity losses from Angel Pharmaceuticals increased from $0.3 million to $0.9 million.
• Stock-based compensation increased to $2.8 million from $1.2 million year-over-year.
• Cash, cash equivalents, and marketable securities totaled $202.9 million as of September 30, 2026, up from $56.8 million in December 2025, primarily due to $189.4 million in proceeds from a Q1 follow-on offering.
• Management projects current cash reserves will fund operations into the second quarter of 2028.

Guidance and Future Outlook:

• Two lead programs are prioritized: the registrational Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma (PTCL) and the Phase 2 Sierra 1 trial in atopic dermatitis (AD).
• Anticipated 2027 milestones include: interim futility analysis for PTCL (Q1 2027), preliminary AD data from partner Angel (March 2027), HS Phase 1b results (H1 2027), and AD Phase 2 data (Q3 2027).
• PTCL top-line data is targeted before the end of 2027; if successful, Phase 3 for AD could commence in 2028.
• Management emphasizes a strategy to generate significant pipeline value in 2027 across four key indications: PTCL, AD, hidradenitis suppurativa (HS), and asthma.

Business Segments and Product Lines:

• Socalitinib (Lead Asset): A first-in-class selective ITK inhibitor targeting Th17 and Th2 pathways.
• PTCL: Phase 3 trial enrollment on track; event-driven futility analysis planned for Q1 2027 with no interim efficacy data release.
• Atopic Dermatitis: Sierra 1 Phase 2 trial enrolling ~200 patients; top-line data expected Q3 2027. Partner Angel Pharmaceuticals completed enrollment in Cohort 1 (24 patients) with data anticipated March 2027; Cohort 2 enrollment began November 2026.
• Hidradenitis Suppurativa (HS): Phase 1b trial initiated in September targeting 25 patients at 200mg BID; enrollment ahead of schedule with data expected H1 2027.
• Asthma: Trial design includes both T2 and non-T2 populations; planned to initiate in Q1 2027 with an interim futility analysis option.
• ALPS: Initial data from three NIAID-led patients shows safety and efficacy; IND transfer to Corvus planned to expand centers and include pediatric patients.

Market and Competitive Landscape:

• Socalitinib's oral mechanism distinguishes it from injectable biologic competitors in HS and addresses unmet needs in non-T2 asthma (up to 40% of patients).
• In PTCL, no fully FDA-approved therapies currently exist, positioning socalitinib for significant value.
• Unique immunologic profile supports efficacy in patients who have failed Dupixent (anti-IL-4R) or JAK inhibitors, with no observed cross-resistance.
• Biomarker data suggests Asian populations may have a stronger Th17 component, aligning with the drug's mechanism and validating the partner trial in China.

Risks and Challenges:

• Futility Risk: The PTCL trial includes a potential futility analysis in Q1 2027 which could lead to trial termination if the independent data monitoring committee deems insufficient progress.
• Clinical Execution: Reliance on partnership success with Angel Pharmaceuticals for global data in China and potential delays in data readouts due to blinded follow-up periods.
• Regulatory & Dosing Uncertainty: Pediatric dosing for ALPS remains to be determined through FDA discussions; pricing and commercialization strategies are too early to define.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing the "fascinating immunologic properties" and favorable safety profile of socalitinib.
• Management highlighted the strategic value of the drug's broad mechanism (modulating Th17 and Th2) and its potential to reset the immune system.
• Executives expressed strong belief in the drug's ability to serve as both upfront and later-line therapy across the target indications.

Analyst Questions and Answers:

• Timeline Shifts: Explained that the AD data readout delay from Angel was to ensure full 12-week treatment and 30-day follow-up while maintaining blinding, not due to enrollment issues.
• PTCL Data Disclosure: Clarified that only the futility decision (continue/stop) will be announced in Q1 2027; efficacy data will not be released unless the trial is terminated early.
• HS Benchmarks: Management expects HISCAR-50 rates of 50-60% and HISCAR-75 rates of ~30% to deem the oral agent competitive.
• AD Patient Profile: Confirmed the trial includes patients who have failed biologics (Dupixent) or JAK inhibitors, supporting use in the relapse setting or potentially as first-line therapy.
• Asthma Enrollment: Defined T2/non-T2 thresholds (eosinophils >150, FeNO >25) and confirmed trial start in Q1 2027 was a strategic choice to avoid holiday periods rather than a regulatory delay.
• ALPS Transition: IND transfer aims to control the study for pediatric expansion; current dosing (200mg BID) is consistent with adult trials but may adjust for children.

Other Key Points:

• A recent Memorial Sloan Kettering study using spatial transcriptomics supports socalitinib's mechanism by showing GATA3 signaling blockade in cutaneous T-cell lymphoma, relevant to both PTCL and AD.
• Preclinical data indicates the drug reduces fibrosis, a key factor in HS treatment.
• Significant interest was noted in the HS trial with rapid enrollment.
• Management confirmed that safety data from the ALPS study included no grade 3 or 4 adverse events over one year of treatment.